Latest Headlines

Latest Headlines

Sanofi manufacturing glitch yields insulin pen shortage

Citing a "technical incident" at a manufacturing plant in Frankfurt, Germany, Sanofi ($SNY) reports that a worldwide shortage of the Apidra Solostar insulin pen will begin this month. The incident,

Court upholds $442M Plavix judgment against Apotex

Bristol-Myers Squibb ($BMY) and Sanofi ($SNY) may finally get their money from Plavix copycat Apotex--but it won't be as much as the two companies wanted. A U.S. appeals panel upheld a trial court's

Genzyme's Ireland site expanded

Sanofi ($SNY) has expanded its Genzyme unit in Waterford, Ireland, 10 years after establishing it. CEO Christopher Viehbacher (photo) says was on hand with local officials at the inauguration of the

Sanofi's Viehbacher sees green lights ahead for Shantha

Admitting "a setback" with its Shantha acquisition after the World Health Organization recalled and destroyed the SHAN5 vaccine in May 2010, Sanofi ($SNY) CEO Chris Viehbacher (photo) says he remains

Sanofi amps up Indian vax plant with $300M investment

Indian newspapers are abuzz with Sanofi's ($SNY) vaccine play in that country. On a tour there, CEO Chris Viehbacher (photo) touted Sanofi's $300 million investment in a "state-of-the-art"

Sanofi boosts India presence with $300M vaccine investment

Lured by growing demand in emerging markets, Sanofi ($SNY) CEO Chris Viehbacher (photo) says his company's Sanofi Pasteur unit plans to open a vaccine manufacturing plant in India--which is slated to

Gardasil bests Cervarix in cost effectiveness battle

According to a study published on the British Medical Journal's website, Merck's ($MRK) and Sanofi's ($SNY) HPV vaccine Gardasil is more cost effective than GlaxoSmithKline's ($GSK) Cervarix. In the

Gardasil wins an HPV cost-effectiveness match-up

The U.K.'s penchant for cost-effectiveness study has lit upon human papillomavirus vaccines. Health Protection Agency researchers compared GlaxoSmithKline's Cervarix shot with Merck and Sanofi's

No consolation for Sanofi as Genzyme scrambles

Genzyme's ongoing manufacturing problems certainly vindicate Sanofi's skepticism during merger talks earlier this year. And supply constraints affecting key Genzyme drugs mean Sanofi ($SNY) didn't

EMA calls for limits on Sanofi's Multaq

European regulators have wrapped up their safety review on Sanofi's ($SNY) heart drug Multaq. The good news is the European Medicines Agency confirmed Multaq's benefits outweigh its risks. The bad